- Home
- WKC vs AUPH Comparison
WKC vs AUPH Comparison
Compare WKC & AUPH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- WKC
- AUPH
- Stock Information
- Founded
- WKC 1984
- AUPH 1993
- Country
- WKC United States
- AUPH Canada
- Employees
- WKC N/A
- AUPH N/A
- Industry
- WKC Oil Refining/Marketing
- AUPH Biotechnology: Pharmaceutical Preparations
- Sector
- WKC Energy
- AUPH Health Care
- Exchange
- WKC Nasdaq
- AUPH Nasdaq
- Market Cap
- WKC 1.5B
- AUPH 1.4B
- IPO Year
- WKC N/A
- AUPH 1999
- Fundamental
- Price
- WKC $25.27
- AUPH $12.84
- Analyst Decision
- WKC Hold
- AUPH Strong Buy
- Analyst Count
- WKC 5
- AUPH 3
- Target Price
- WKC $29.40
- AUPH $12.00
- AVG Volume (30 Days)
- WKC 726.9K
- AUPH 1.6M
- Earning Date
- WKC 10-23-2025
- AUPH 11-06-2025
- Dividend Yield
- WKC 3.15%
- AUPH N/A
- EPS Growth
- WKC N/A
- AUPH N/A
- EPS
- WKC N/A
- AUPH 0.42
- Revenue
- WKC $38,747,200,000.00
- AUPH $260,111,000.00
- Revenue This Year
- WKC N/A
- AUPH $16.92
- Revenue Next Year
- WKC $2.16
- AUPH $14.43
- P/E Ratio
- WKC N/A
- AUPH $30.31
- Revenue Growth
- WKC N/A
- AUPH 25.59
- 52 Week Low
- WKC $22.71
- AUPH $6.43
- 52 Week High
- WKC $31.71
- AUPH $12.87
- Technical
- Relative Strength Index (RSI)
- WKC 38.17
- AUPH 68.38
- Support Level
- WKC $26.49
- AUPH $12.06
- Resistance Level
- WKC $25.93
- AUPH $12.82
- Average True Range (ATR)
- WKC 0.57
- AUPH 0.37
- MACD
- WKC -0.11
- AUPH -0.04
- Stochastic Oscillator
- WKC 7.66
- AUPH 92.30
About WKC World Kinect Corporation
World Kinect Corp is an energy management company involved in providing supply fulfillment, energy procurement advisory services, and transaction and payment management solutions to commercial and industrial customers. It sells and delivers liquid fuels, natural gas, electricity, renewable energy, and other sustainability solutions. The company operates in three reportable segments consisting of aviation, land, and marine. The company earns the majority of its revenue from the Aviation segment.
About AUPH Aurinia Pharmaceuticals Inc
Aurinia Pharmaceuticals Inc is a biopharmaceutical company focused on delivering therapies to people living with autoimmune diseases with high unmet medical needs. The company developed LUPKYNIS (voclosporin), the first FDA-approved oral therapy for the treatment of adult patients with active lupus nephritis. It is also developing AUR200, a dual inhibitor of B cell activating factor (BAFF) and a proliferation-inducing ligand (APRIL), for the potential treatment of autoimmune diseases.